This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

Bridging the gap between basic scientific advances and the understanding of liver disease — the extensively revised new edition of the premier text in the field. The latest edition of The Liver: Biology and Pathobiology remains a definitive volume in the field of hepatology, relating advances in biomedical sciences and engineering to understanding of liver structure, function, and disease pathology and treatment. Contributions from leading researchers examine the cell biology of the liver, the pathobiology of liver disease, the liver’s growth, regeneration, metabolic functions, and more. Now in its sixth edition, this classic text has been exhaustively revised to reflect new discoveries in biology and their influence on diagnosing, managing, and preventing liver disease. Seventy new chapters — including substantial original sections on liver cancer and groundbreaking advances that will have significant impact on hepatology — provide comprehensive, fully up-to-date coverage of both the current state and future direction of hepatology. Topics include liver RNA structure and function, gene editing, single-cell and single-molecule genomic analyses, the molecular biology of hepatitis, drug interactions and engineered drug design, and liver disease mechanisms and therapies. Edited by globally-recognized experts in the field, this authoritative volume: Relates molecular physiology to understanding disease pathology and treatment Links the science and pathology of the liver to practical clinical applications Features 16 new “Horizons” chapters that explore new and emerging science and technology Includes plentiful full-color illustrations and figures The Liver: Biology and Pathobiology, Sixth Edition is an indispensable resource for practicing and trainee hepatologists, gastroenterologists, hepatobiliary and liver transplant surgeons, and researchers and scientists in areas including hepatology, cell and molecular biology, virology, and drug metabolism.

This book covers the huge advances made in clinical diagnosisenabling earlier detection, while addressing the recent progressmade in treatment of hepatocellular carcinoma (HCC) to enablesuccessful therapy. It draws on the expertise of an internationally recognizedauthor famed for his understanding, knowledge and efforts indefining terms and diagnosis in this area. The text reviews the full range of pathological information ofHCC based on the study of surgical cases and biopsy materials,along with images, to help compare findings that may be encounteredby pathologists. It also makes special reference to developments inearly stage HCC detection and premalignant lesions which canincrease effective treatment.

1. Epidemiology / Trishe Y.-M. Leong and Anthony S.-Y. Leong -- 2. Liver terminology and anatomy / Steven M. Strasberg -- 3. Assessment of liver function / Darren V. Mann -- 4. Prevention / Michael C. Kew -- 5. Screening / Morris Sherman -- 6. Presentation and diagnosis / Dario Ribero, Gareth Morris-Stiff and Jean-Nicolas Vauthey -- 7. Tumor markers / John Y. H. Chan and Zhi Wang -- 8. Imaging / Simon S. M. Ho and Simon C. H. Yu -- 9. Pathology / Anthony S.-Y. Leong, Trishe Y.-M. Leong and Pongsak Wannakrairot -- 10. Molecular aspects / John Y. H. Chan, Kenneth K. H. Lee, Yiu-Loon Chui and Macus T. Kuo -- 11. Staging / Justin M. Burns and Frederick L. Greene -- 12. Selection of patients for liver resection / Eric C. H. Lai, W. Y. Lau and Darren V. Mann -- 13. Problems associated with liver resection in cirrhotic patients / Cheng-Chung Wu -- 14. Preoperative portal vein embolization / Takuya Hashimoto and Masatoshi Makuuchi -- 15. Intraoperative ultrasound / Guido Torzilli and Henri Bismuth -- 16. Surgical treatment / Jacques Belghiti -- 17. Anterior approach using the hanging technique / Jacques Belghiti and Barbara Alkofer -- 18. Segment-based liver resection / W. Y. Lau and Eric C. H. Lai -- 19. Intrahepatic glissonian approach / Bernard Launois and Khoon Hean Tay -- 20. Ultrasonically guided segmentectomy and subsegmentectomy / Taku Aoki, Norihiro Kokudo and Masatoshi Makuuchi -- 21. Isolated caudate lobe resection (resection of couinaud segment 1) / Shu-You Peng -- 22. Laparoscopic Liver Resection / Rong Liu -- 23. Techniques of vascular control and protective strategies for parenchymal transection / Markus K. Müller, Henrik Petrowsky and Pierre-Alain Clavien -- 24. Techniques of liver transection / Eric T. Castaldo and C. Wright Pinson -- 25. Radiofrequency-assisted liver resection / Long R. Jiao and Nagy A. Habib -- 26. Cytoreductive (tumor-debulking) surgery / Eric C. H. Lai and W. Y. Lau -- 27. Cryosurgery / George Petrou and David L. Morris -- 28. Liver transplantation / Chao-Long Chen and Allan M. Concejero / 29. Local ablative therapy / Tito Livraghi -- 30. Regional therapy / W. Y. Lau and Eric C. H. Lai -- 31. Systemic chemotherapy / Thomas W. T. Leung -- 32. Neoadjuvant/adjuvant/chemoprevention therapy and tumor downstaging / W. Y. Lau and Eric C. H. Lai -- 33. Management of portal vein tumor thrombus / W. Y. Lau, Eric C. H. Lai and Simon C. H. Yu -- 34. Palliative care / Winnie Yeo and Anthony T. C. Chan -- 35. Management of specific complications / Eric C. H. Lai and W. Y. Lau -- 36. Management of acute liver failure / A. R. Nitin Rao -- 37. Extracorporeal energy therapy / Eric C. H. Lai and W. Y. Lau

The book is edited by a multidisciplinary team, with an international group of contributors. After discussing the basic and clinical aspects of HCC the main focus of the book is on diagnosis and therapy. The book is both authoritative and practical, providing expert guidance on the various techniques used in diagnosis, such as ultrasound, CT and MRI and the appropriate therapeutic options, for example, surgical resection, transcatheter therapies and radiofrequency ablation. It is fully illustrated throughout in both colour and black and white.

Hepatocellular carcinoma is one of the most common fatal malignan cies of mankind. Up to a few decades ago it was looked upon as a cancer which aroused mainly academic concern but relatively little clinical interest, because its therapy and prognosis had a most un favorable outlook. Indeed, it was mostly recognized only at autopsy. Recently this pessimism has radically changed and is disappearing to a rapidly accelerating degree. Many of the scientific contributions at this change in outlook are the result of research in the Far East, first, Japan and then gradually extending to its neighbors. The introduction of experimental hepatocarcinogens by Yoshida more than 50 years ago may have been one of the first important steps. Hepatocellular car cinoma shows a characteristic geographical distribution. With the highest incidence in China, Taiwan, Southeast Asia and sub-Saharan Africa, followed by southern and eastern Europe, while generally the incidence is rather low in western and northern Europe and North and South America.

This book comprehensibly describes the clinical details of anatomic hepatic resection using the Glissonean pedicle approach for hepatocellular carcinoma. It includes all aspects of the surgical anatomy of the liver, preoperative management of patients, surgical techniques, and intraoperative key points to prevent postoperative complications. The first three chapters provide a general introduction to the clinical anatomy of the liver, preoperative management of patients with hepatocellular carcinoma, basic techniques for hepatic resection using the Glissonean approach, and the application of dye staining in anatomic hepatic resection. Subsequent chapters present the technical details of anatomical segmentectomy (Couinaud’s classification), sectionectomy and hemi-hepatectomy for hepatocellular carcinoma using the modified suprahilar Glissonean approach. All of these hepatectomies can be performed using simple and easily available surgical instruments. In addition, it discusses precise transection of the deepest hepatic parenchyma guided by methylene blue staining. It is a useful and timely reference for hepatobiliary surgeons, clinical staff, and medical students.

This book aims to illuminate the causes, incidence, and treatments of Hepatocellular Carcinoma(HCC) or liver cancer in the politically important and societally diverse region of the Middle East. Taking a flexible and inclusive view, it examines the influences of geography, crops and diet, ethnicity, and local behavior on both diagnosis and outcomes of this disease. Understanding the different causes of liver cancer enables effective strategies for both prevention and early diagnosis while knowledge of the different treatment modalities, their uses and limitations, availability and costs, works to inform rational treatment provision and selection. Divided into four sections, this book considers the causes and clinical syndromes associated with HCC, provides a detailed overview of clinical HCC and treatment modalities, describes country-specific clinical HCC experience and practice, and considers future needs and the potential for HCC collaborations across the region. Liver Cancer in the Middle East is a useful resource for clinicians seeking insight into the second highest cause of death from cancer worldwide, governments planning social and medical services for their peoples, as well as for international aid agencies prioritizing donations.

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.